Boehringer Ingelheim: Carcinoma, Non-Small-Cell Lung trials
The registry lists 68 Carcinoma, Non-Small-Cell Lung studies with Boehringer Ingelheim as lead sponsor. 3 are open to participants now and 53 have results posted.
Phase 1 21Phase 2 10Phase 3 14Phase 4 3No phase 20(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Real-world Outcome of Zongertinib in Japan (J-HERZ)Not yet recruitingNCT07926308
- Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD MutationsRecruitingNCT07195695Phase 3
- Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)RecruitingNCT04886804Phase 1
- Non-interventional Study for Real-world Data of Afatinib Treatment in First-line Setting and of Subsequent Therapies for Patients With Advanced Epidermal Growth Factor Receptor (EGFR) Mutation-positive Lung AdenocarcinomaCompletedNCT04795245Results posted
- Real-World Effectiveness of Afatinib (Gilotrif) Following Immunotherapy in the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: A Multi-Site Retrospective Chart Review Study in the U.S.CompletedNCT04750824Results posted
- A Study in the United States Using Electronic Medical Records (EMR) to Assess Effectiveness of Afatinib (Gilotrif) Following Pembrolizumab and Chemotherapy in the Treatment of Metastatic Squamous Cell Carcinoma of the LungCompletedNCT04552535Results posted
- The Study Observes Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung CancerCompletedNCT04206787Results posted
- The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by OsimertinibCompletedNCT04179890Results posted
- This Study Tests How BI 754111 is Distributed in Patients With Advanced Non-small Cell Lung Cancer or Patients With Head and Neck Cancer Who Are Treated With BI 754091TerminatedNCT03780725Phase 1Results posted
- A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid TumoursCompletedNCT03468426Phase 1Results posted
- Afatinib Osimertinib Sequencing NISCompletedNCT03370770Results posted
- A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have SpreadTerminatedNCT03166631Phase 1Results posted
- Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the LungCompletedNCT03157089Phase 2Results posted
- This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.CompletedNCT03156114Phase 1Results posted
- Post Marketing Surveillance of Nintedanib in Indian Patients With Non-small Cell Lung Cancer (NSCLC) After First-line TherapyCompletedNCT03017885Results posted
- Real World Data on Gi(l)Otrif® Dose AdjustmentCompletedNCT02751879Results posted
- Investigation of the Effect of Nintedanib on the Pharmacokinetics of a Combination of Ethinylestradiol and Levonorgestrel in Patients With Non-small Cell Lung CancerTerminatedNCT02751385Phase 1Results posted
- Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)TerminatedNCT02695290Phase 4Results posted
- LUME BioNIS: a Biomarker Study in Patients With NSCLCCompletedNCT02671422Results posted
- Nintedanib and Weekly Docetaxel in Lung AdenocarcinomaCompletedNCT02668393Phase 1Results posted
- Afatinib in NSCLC With HER2 MutationCompletedNCT02597946Phase 2Results posted
- Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or OlderCompletedNCT02514174Phase 4Results posted
- Evaluation of the Impact of Nurse-led Telephone on Treatment ComplianceTerminatedNCT02483416Results posted
- Evaluate the Impact of Afatinib on Quality of Life and Symptom Burden of Greek Subjects With Advanced NSCLC in Routine Patient Care SettingsCompletedNCT02440854Results posted
- Nintedanib Plus Docetaxel in Japanese Patients With Adenocarcinoma Subtype Non-small Cell Lung Cancer After Failure of First Line ChemotherapyCompletedNCT02300298Phase 1Results posted
- GIOTRIF rPMS in Korean Patients With NSCLCCompletedNCT02285361Results posted
- Phase III Trial BI 695502 Plus Chemotherapy vs. Avastin® Plus Chemotherapy in Patients With Lung CancerCompletedNCT02272413Phase 3Results posted
- LUME-Columbus: Nintedanib Plus Docetaxel in Advanced Non-small Cell Lung Cancer With Translational ResearchTerminatedNCT02231164Phase 3Results posted
- Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) MutationCompletedNCT02208843Phase 4Results posted
- Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)CompletedNCT02191891Phase 1Results posted
- Long-term Observation PMS for AfatinibCompletedNCT02131259Results posted
- GIOTRIF in First Line Therapy of Advanced NSCLC With EGFR-mutationsCompletedNCT02047903Results posted
- Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) MutationsCompletedNCT02044380Phase 3Results posted
- Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR MutationCompletedNCT01953913Phase 3Results posted
- An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)CompletedNCT01853826Phase 3Results posted
- ADAM-Afatinib Diarrhea Assessment and ManagementCompletedNCT01814553Phase 3Results posted
- A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M MutationsCompletedNCT01647711Phase 1Results posted
- LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based ChemotherapyCompletedNCT01523587Phase 3Results posted
- A Phase I/II Study of Continuous Oral Treatment With BIBF 1120 Added to Standard Gemcitabine/Cisplatin Therapy in First Line NSCLC Patients With Squamous Cell Histology.CompletedNCT01346540Phase 1Results posted
- BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)CompletedNCT01121393Phase 3Results posted
- Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung CancerCompletedNCT01090011Phase 1Results posted
- LUX-Lung 5: Afatinib Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following Afatinib Monotherapy in Non-small Cell Lung Cancer Patients Failing Erlotinib or GefitinibCompletedNCT01085136Phase 3Results posted
- A Phase II Trial of Afatinib(BIBW 2992) in Third-line Treatment for Patients With Stage IIIB/IV Adenocarcinoma of the Lung Harbouring Wild-type Epidermal Growth Factor Receptor[EGFR]CompletedNCT01003899Phase 2Results posted
- Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune®) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or GefitinibCompletedNCT00993499Phase 1Results posted
- BIBF 1120 in Combination With Pemetrexed in Advanced Non Small Cell Lung Cancer (NSCLC)TerminatedNCT00979576Phase 1Results posted
- BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR MutationCompletedNCT00949650Phase 3Results posted
- BIBF 1120 + Docetaxel (Japan) in Patients With Advanced Non-small-cell Lung Cancer, Phase ICompletedNCT00876460Phase 1Results posted
- Trial of BI 6727 (Volasertib) Monotherapy and BI 6727 in Combination With Pemetrexed Compared to Pemetrexed Monotherapy in Advanced NSCLCCompletedNCT00824408Phase 2Results posted
- Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLCCompletedNCT00806819Phase 3Results posted
- LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung CancerCompletedNCT00805194Phase 3Results posted
- BIBW2992 (Afatinib) in Advanced (EGFR-FISH +) NSCLC (Non Small Cell Lung Cancer) PatientsCompletedNCT00796549Phase 2Results posted
- Single-arm Trial of BIBW 2992 (Afatinib) in Demographically and Genotypically Selected NSCLC PatientsCompletedNCT00730925Phase 2Results posted
- LUX-Lung 4: BIBW 2992 (Afatinib) Phase I Trial in Advanced Non Small Cell Lung Cancer Patients & Phase II Trial in Non Small Cell Lung Cancer Patients Failing Erlotinib or GefitinibCompletedNCT00711594Phase 2Results posted
- BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)CompletedNCT00656136Phase 3Results posted
- LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating MutationsCompletedNCT00525148Phase 2Results posted
- Efficacy and Safety of BI 2536 in Advanced or Metastatic Non Small Cell Lung CancerCompletedNCT00376623Phase 2Results posted
- A Study to Compare Tissue and Liquid Biopsies in People With Different Types of CancerActive, not recruitingNCT05708599Not applicable
- A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking EzabenlimabActive, not recruitingNCT05068102Phase 1
- VARGADO - Vargatef in 2nd-line Therapy of Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02392455
- Dose Escalation Study of BI 2536 With Pemetrexed in Previously Treated Patients With Non-small-cell Lung CancerCompletedNCT02211833Phase 1
- Single Dose Escalation Study of 131I-Sibrotuzumab in Patients With Advanced or Metastatic Non-small Cell Lung CancerTerminatedNCT02209727Phase 1
- Biodistribution Study With 186 Re-labelled Humanised Monoclonal Antibody BIWA 4 in Patients With Non-small Cell Lung CancerCompletedNCT02204059Phase 1
- A Dose Escalation Study of BIBF 1120 Together With Paclitaxel and Carboplatin in Patients With Advanced Stage Non-small-cell Lung CancerCompletedNCT02182232Phase 1
- Dose Escalation of BIBF 1120 Combined With Pemetrexed in Advanced Non Small Cell Lung CancerCompletedNCT02182102Phase 1
- Efficacy and Safety of Oral Treatment With BIBF 1120 ES in Advanced Non-small-cell Lung CancerCompletedNCT02182050Phase 2
- Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC)Approved for marketingNCT01931306
- Afatinib Expanded Access ProgramApproved for marketingNCT01649284
- LUX Lung Special Access Scheme Australia Named Patient Use (NPU)Approved for marketingNCT01209650